射干的化学成分研究(Ⅱ)

目的 研究中药射干的化学成分。方法 采用硅胶拄色谱及Sephadex LH-20等色谱技术分离纯化，根据理化性质及色谱数据鉴定结构。结果 从射干乙醇提取物的醋酸乙酯萃取部分分得3个化合物，分别为异鼠李素(isorhamnetin，Ⅹ)、粗毛豚草素(hispidulin，Ⅺ)、白射干素(dichotomitin，Ⅻ)，从乙醇提取液正丁醇萃取部分分离得到4个化合物，分别为：鸢尾苷(iridin，ⅩⅢ)、野鸢尾苷(tectoridin，ⅩⅣ)、胡萝卜苷(daucosterol，ⅩⅤ)、维太菊苷(vittadinoside or stigmasterol-3-O-glucoside，ⅩⅥ)。结论 其中化合物Ⅺ为首次从该植物中分得。     

肉苁蓉药材与盐生肉苁蓉培养细胞的主要成分对比研究

目的研究肉苁蓉药材与盐生肉苁蓉培养细胞的苯乙醇苷类成分差异。方法利用傅里叶变换红外光谱(FTIR)和HPLC技术进行成分对比分析。结果FTIR的分析结果表明，盐生肉苁蓉培养细胞的红外指纹谱图与肉苁蓉药材具有一定相似性；HPLC的分析结果表明，盐生肉苁蓉细胞中所含的主要成分和肉苁蓉药材相似，只是含量有差异。结论从整体上看，盐生肉苁蓉培养细胞中所含成分种类较多，且大部分含量较高，其中洋丁香酚苷(类叶升麻苷)和松果菊苷的含量大幅度高于肉苁蓉药材。     

苯丙素苷及其类似物的合成研究

利用葡萄糖6位羟基活性较高的特性, 2-(取代)苯乙基-β-D-吡喃葡萄糖苷在低温条件下直接与(取代)肉桂酰氯反应,区域选择性地生成6位酰化的葡萄糖苷,利用此方法很方便的得到了13个苯丙素苷类似物,利用1H NMR 和13C NMR方法确证了他们的结构.     

梅花参化学成分研究(Ⅰ)

目的：研究梅花参体内的皂苷类化合物。方法：从梅花参体内提取得到总皂苷，应用多种色谱技术对其进行分离纯化．根据化舍物的理化性质和波谱数据鉴定其结构。结果：分离得到了1个三萜皂苷类化合物，应用化学方法和各种光谱方法鉴定其结构为：3-O-[3-D-甲基-β-D-吡喃葡萄糖-(1-3)-β-D-吡喃奎诺糖-(1→4)-βD吡喃奎诺糖．(1→2)4’-O-磺酸钠-β—D-吡喃木糖]-海参烷-9-烯-3β，12α，17β，25β-四醇。结论：该化合物为一新化合物，命名为梅花参皂苷D。     

海金沙草中一个新的甾体苷类化合物的分离和结构鉴定

目的：研究海金沙草（Lygodium japonicum）的化学成分。方法：采用硅胶柱层析、Sephadex LH-20柱层析、ODS柱层析等方法进行分离和纯化化学成分，结合化学方法和波谱方法进行结构鉴定。结果：从海金沙草中分离得到4个化合物，分别为：（24R）-stigmastan-3β，5α，6β-triol 3，O-β-D-glucopyranoside（1），6-O-p-coumaroyl-D-glucopyranose（2），6-0-caffeoyl-D-glucopyranose（3），and 1-O-（E）-caffeoyl-β-D-gentiobiose（4）。结论：化合物1为新化合物，化合物2,3，4为首次从海金沙科中分离得到。     

毛细管电泳法测定娑罗子药材中的黄酮苷类成分

目的:建立高效胶束毛细管电泳法分离测定娑罗子药材中的黄酮苷类成分的分析方法。方法:应用 HPCE 对娑罗子中分离得到的3种黄酮苷进行分析测定,以0.2mol·L~(-1)硼砂-0.06mol·L~(-1)SDS(含15%乙腈,pH 为9.0)的缓冲液为电泳介质,压力进样,在25℃,20kV 恒压下电泳分离,并在270nm 波长处检测。结果:娑罗子中的3种黄酮苷在30min 内可达到分离。结论:该方法可用于娑罗子药材及其制剂中黄酮苷类成分的分析。     

Terpenoidal constituents of Eucalyptus loxophleba ssp. lissophloia

Context: Eucalyptus has been a source of a number of biologically active compounds. The anti-leishmanial activity of terpenoids from Eucalyptus loxophleba (Benth.) ssp. lissophloia (Myrtaceae) has not yet been investigated.

Objective: Isolation of the terpenoidal constituents for evaluation of in vitro anti-leishmanial activity against the Leishmania donovani (Dd8 strain) promastigotes.

Materials and methods: The chloroform–methanol (8:2) extract of dried leaves of Eucalyptus loxophleba was used to isolate terpenoidal constituents employing solvent partitioning, column chromatography and preparative high performance liquid chromatography and characterized from spectral data. The anti-leishmanial activity of the isolated compounds was tested in vitro using an Alamar blue assay against a culture of L. donovani (Dd8 strain) promastigotes.

Results: Two new naturally occurring triterpenes, named loxanic acid and 3-acetyl loxanic acid together with four known ursane triterpenoids and one bis-monoterpene glycoside, cuniloside B isolated from the leaves showed anti-leishmanial activity (IC₅₀ 133 to 235 μM) against the promastigotes of the tested strain.

Conclusion: The terpenes isolated from the leaves of E. loxophleba showed moderate anti-leishmanial activity.     

Pharmacokinetics,tissue distribution and excretion study of a furostanol glycoside-based standardized fenugreek seed extract in rats

Abstract

The furostanol glycoside isolated from the seed of fenugreek (SFSE-G) has an array of pharmacological activities. To date, no validated high-performance liquid chromatography (HPLC) method has been reported for quantification of SFSE-G in biological samples. Hence, the aim of the present study was to study the pharmacokinetics, tissue distribution and excretion profiles of SFSE-G after oral administration in rats. A rapid, sensitive, selective, robust and reproducible HPLC method has been developed for determination of SFSE-G in the rat biological samples. The chromatographic separation was accomplished on a reversed-phase C18 column using formic acid and acetonitrile (80:20) as mobile phase at a flow rate of 1.0?mL/min and 274?nm as a detection wavelength. The assay was linear for SFSE-G with the correlation coefficients (R²) >0.996. The analytes were stable during samples storage and handling, and no matrix effects were observed. After oral dosing of SFSE-G at a dose of 200?mg/kg, the elimination half-life was app. 40.10?h. It showed relatively slowly distribution and eliminated in urine and feces after 24?h, and could be detected until 108?h post-dosing. Following oral single dose (200?mg/kg), SFSE-G was detected in lung and brain which indicated that it could cross the blood–brain barrier. It is a major route of elimination is excretion through urine and feces. In conclusion, oral administration of SFSE-G showed slow distribution to tissues, such as lung and brain, but showed fast renal elimination.     

舒血宁联合脑苷肌肽治疗血管性痴呆的疗效研究

目的 观察舒血宁联合脑苷肌肽治疗血管性痴呆患者的疗效及对精神行为症状的改善情况.方法 将58例血管性痴呆患者随机分为舒血宁联合脑苷肌肤治疗的观察组和单纯脑苷肌肤治疗的对照组,治疗结束后观察两组患者的临床疗效、简易智能量表(MMSE)、日常生活活动能力量表(ADL)评分以及安全性评价.结果 治疗后,观察组有效率为89.66％,优于对照组的72.41％,组间差异有统计学意义(P＜0.05).治疗后两组患者的MMSE、ADL评分均较治疗前明显增加,差异均有统计学意义(P＜0.05);而组间比较,观察组的MMSE、ADL评分均较对照组明显增加,差异亦有统计学意义(P＜0.05),且均未出现不良反应.结论 舒血宁联合脑苷肌肽治疗血管性痴呆患者,不仅疗效较佳,安全性高,而且可有效改善患者的精神行为症状.